These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 38357305)

  • 21. Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients.
    Silvertown JD; Lisle C; Semenuk L; Knapp C; Jaynes J; Berg D; Kaul N; Lachapelle J; Richardson L; Speevak M; Sarras H; Berman DM; Carter R; Feilotter H; Feltis T
    Mol Diagn Ther; 2023 Jan; 27(1):87-103. PubMed ID: 36194351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Case report:
    Lazzari C; Pecciarini L; Doglioni C; Pedica F; Gajate AMS; Bulotta A; Gregorc V; Cangi MG
    Front Oncol; 2022; 12():1038774. PubMed ID: 36419889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer.
    Laetsch TW; Hong DS
    Clin Cancer Res; 2021 Sep; 27(18):4974-4982. PubMed ID: 33893159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-Institution Experience of Larotrectinib Therapy for Patients With
    Elghawy O; Barsouk A; Heidlauf A; Chen S; Cohen RB; Sun L
    J Endocr Soc; 2024 Aug; 8(10):bvae158. PubMed ID: 39295960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib.
    Wu WC; Chen MH
    Front Oncol; 2022; 12():1031396. PubMed ID: 36703785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NTRK Fusion-positive Non-small-cell Lung Cancer: The Diagnosis and Targeted Therapy.
    Haratake N; Seto T
    Clin Lung Cancer; 2021 Jan; 22(1):1-5. PubMed ID: 33272813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs.
    Han SY
    Pharmaceuticals (Basel); 2021 Jun; 14(7):. PubMed ID: 34209967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Case Report: Identification of a novel
    Yu QX; Zhao WJ; Wang HY; Zhang L; Qin L; Zhang L; Han JL
    Front Oncol; 2023; 13():1123812. PubMed ID: 37188179
    [No Abstract]   [Full Text] [Related]  

  • 29. Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers.
    Garcia-Foncillas J; Bokemeyer C; Italiano A; Keating K; Paracha N; Fellous M; Marian M; Fillbrunn M; Gao W; Ayyagari R; Lassen U
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in China.
    Xu Y; Shi X; Wang W; Zhang L; Cheung S; Rudolph M; Brega N; Dong X; Qian L; Wang L; Yuan S; Tan DSW; Wang K
    NPJ Precis Oncol; 2023 Aug; 7(1):75. PubMed ID: 37567953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas: A Review.
    Haddad R; Elisei R; Hoff AO; Liu Z; Pitoia F; Pruneri G; Sadow PM; Soares F; Turk A; Williams MD; Wirth LJ; Cabanillas ME
    JAMA Oncol; 2023 Aug; 9(8):1132-1141. PubMed ID: 37289450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors.
    Hibar DP; Demetri GD; Peters S; Davies J; Humblet O; Maund SL; Perez L
    PLoS One; 2022; 17(8):e0270571. PubMed ID: 35939431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer.
    Carlson JJ; Italiano A; Brose MS; Federman N; Lassen U; Kummar S; Sullivan SD
    Am J Manag Care; 2022 Jan; 28(2 Suppl):S26-S32. PubMed ID: 35201681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults.
    Bebb DG; Banerji S; Blais N; Desmeules P; Gill S; Grin A; Feilotter H; Hansen AR; Hyrcza M; Krzyzanowska M; Melosky B; Noujaim J; Purgina B; Ruether D; Simmons CE; Soulieres D; Torlakovic EE; Tsao MS
    Curr Oncol; 2021 Jan; 28(1):523-548. PubMed ID: 33467570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. China special issue on gastrointestinal tumors-NTRK fusion in a large real-world population and clinical utility of circulating tumor DNA genotyping to guide TRK inhibitor treatment.
    Qi C; Zhou T; Bai Y; Chen H; Yuan J; Zhao F; Liu C; Ma M; Bei T; Chen S; Zhao X; Chen C; Shen L
    Int J Cancer; 2023 Dec; 153(11):1916-1927. PubMed ID: 36946696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Isolated Leptomeningeal Progression in a Patient with NTRK Fusion+ Uterine Sarcoma: A Case Report.
    Lanman T; Hayden Gephart M; Bui N; Toland A; Nagpal S
    Case Rep Oncol; 2021; 14(3):1841-1846. PubMed ID: 35111018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors.
    Sigal DS; Bhangoo MS; Hermel JA; Pavlick DC; Frampton G; Miller VA; Ross JS; Ali SM
    Oncotarget; 2018 Nov; 9(88):35809-35812. PubMed ID: 30533196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of Entrectinib in a Patient With the First Reported
    Sigal D; Tartar M; Xavier M; Bao F; Foley P; Luo D; Christiansen J; Hornby Z; Maneval EC; Multani P
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1317-1322. PubMed ID: 29118225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Diagnosis and therapy of tumors with NTRK gene fusion].
    Stenzinger A; van Tilburg CM; Tabatabai G; Länger F; Graf N; Griesinger F; Heukamp LC; Hummel M; Klingebiel T; Hettmer S; Vokuhl C; Merkelbach-Bruse S; Overkamp F; Reichardt P; Scheer M; Weichert W; Westphalen CB; Bokemeyer C; Ivanyi P; Loges S; Schirmacher P; Wörmann B; Bielack S; Seufferlein TTW
    Pathologe; 2021 Feb; 42(1):103-115. PubMed ID: 33258061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncogenic fusions: Targeting NTRK.
    Hagopian G; Nagasaka M
    Crit Rev Oncol Hematol; 2024 Feb; 194():104234. PubMed ID: 38122917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.